B. Braun Medical Inc. Initiates Class II Recall of Sodium Chloride Irrigation Due to Particulate Matter
B. Braun Medical Inc. has initiated a voluntary Class II recall of 32,256 bottles of 0.9% Sodium Chloride Irrigation USP due to particulate matter. This event, identified as D-0353-2025, impacts nationwide distribution, necessitating immediate action from procurement and supply chain leaders to quarantine affected lots and secure alternative sourcing for this critical medical product.
FDA Class II Recall: B. Braun Medical's Sodium Chloride Irrigation Affected by Particulate Matter
ChemLifeIntel confirms that B. Braun Medical Inc. has initiated a voluntary Class II recall for 32,256 bottles of its 0.9% Sodium Chloride Irrigation USP, Isotonic Solution for Irrigation, 500 mL Plastic Irrigation Container (PIC). This critical regulatory action, identified under recall number D-0353-2025, was initiated by the firm on March 31, 2025, with the FDA's center classification occurring on April 8, 2025. The primary reason for this recall is the confirmed presence of particulate matter within the product, specifically impacting Lot # J4K936, which carries an expiration date of July 31, 2027. The product, bearing NDC 0264-2201-10, is manufactured by B. Braun Medical, Inc. in Bethlehem, PA, though the recalling firm's address is listed as Irvine, CA. For procurement directors and regulatory affairs heads, this means an immediate need to assess inventory and supply lines. The presence of particulate matter in an irrigation solution can pose significant patient safety risks, including local irritation, infection, or embolization, depending on the nature and size of the particles. A Class II classification indicates that the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. This event directly impacts the reliability of a foundational medical product, demanding swift action to quarantine affected stock and prevent its use in clinical settings. Business development executives should note the potential for reputational damage and the imperative for robust quality assurance in high-volume sterile products.
Immediate Supply Chain and Procurement Implications for Sodium Chloride
The recall of B. Braun Medical Inc.'s 0.9% Sodium Chloride Irrigation USP carries substantial implications for global supply chain resilience, particularly for healthcare providers and distributors. The affected product quantity totals 32,256 bottles, distributed to 12 primary distributors who, in turn, may have further disseminated the product nationwide across the United States. This broad distribution pattern means that a significant number of healthcare facilities, from hospitals to outpatient clinics, are potentially holding affected inventory. Procurement directors must immediately initiate comprehensive inventory checks against Lot # J4K936 to identify and quarantine all affected units. The voluntary, firm-initiated nature of the recall, communicated initially via letter, places the onus on distributors and end-users to act promptly. Failure to do so could result in continued patient exposure to a non-conforming product and subsequent regulatory liabilities. Supply chain VPs face the immediate challenge of managing reverse logistics for the recalled product while simultaneously securing alternative sources for 0.9% Sodium Chloride Irrigation to prevent stockouts. Given the essential nature of sodium chloride for irrigation, any disruption can have direct operational and patient care consequences. Business development executives should recognize the opportunity for alternative suppliers to demonstrate reliability and capture market share during this critical period, while B. Braun Medical Inc. navigates the logistical complexities of a nationwide recall.
Navigating Remediation and Ensuring Future Supply Chain Resilience
The ongoing status of B. Braun Medical Inc.'s Class II recall for 0.9% Sodium Chloride Irrigation USP mandates a clear path for remediation and proactive measures for future supply chain resilience. For B. Braun Medical Inc., the immediate priority is to ensure the complete removal of all affected Lot # J4K936 products from the market and to conduct a thorough root cause analysis for the particulate matter contamination. Regulatory affairs heads at B. Braun must prepare for potential FDA scrutiny regarding their manufacturing processes and quality control systems, as inadequate responses could lead to further regulatory actions beyond the recall. For procurement directors and supply chain VPs reliant on B. Braun Medical Inc., this event underscores the critical need for diversified sourcing strategies. While specific alternative suppliers are not identified in the available intelligence, companies such as Baxter International Inc. and Fresenius Kabi AG are known players in the sterile irrigation solutions market and may be considered. Qualification timelines for new suppliers must be expedited where possible, emphasizing robust quality agreements and audit processes to prevent similar incidents. Business development executives should evaluate the long-term impact on supplier relationships and consider how this event influences future contract negotiations and risk assessments. Proactive engagement with regulatory intelligence platforms like ChemLifeIntel is crucial to monitor B. Braun's remediation efforts and identify any emerging compliance trends that could affect the broader market for sterile pharmaceutical products.